PUBLISHER: IMARC | PRODUCT CODE: 1541128
PUBLISHER: IMARC | PRODUCT CODE: 1541128
The global coronary stents market size reached US$ 11.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.46% during 2024-2032.
Coronary stents are small, self-expanding tubular metallic devices introduced inside narrow coronary arteries to keep them open after a balloon angioplasty procedure. These stents are coated with a medication, which is slowly released to prevent the walls of arteries from plaque buildup and re-narrowing. They also alleviate heart disease symptoms, such as chest pain and shortness of breath, and allow normal flow of blood and oxygen to the heart. As they are minimally invasive (MI) and require shorter recovery time, coronary stents are gaining traction over coronary artery bypass surgeries around the world.
The growing incidence of diabetes, obesity and high blood pressure (BP) is escalating the risk of atherosclerosis disease. This, along with the rising geriatric population, which is more likely to develop cardiovascular diseases (CVDs), represents one of the significant factors impelling the growth of the coronary stent market. Apart from this, the growing popularity of minimally invasive surgeries (MIS) is resulting in the increasing adoption of coronary stents that involve small incision wounds, short hospital stays and fast recovery. Other factors contributing to the market growth include the development of bifurcated stents, improving healthcare infrastructure and rising manufacturing of products using biodegradable materials. Furthermore, the leading market players are introducing advanced products, which is anticipated to drive the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global coronary stents market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, biomaterial, mode of delivery and end user.
Drug-eluting Stents
Bare-metal Coronary Stents
Bioabsorbable Stents
Metallic Biomaterial
Polymeric Biomaterial
Natural Biomaterial
Balloon-expandable Stents
Self-expanding Stents
Hospitals
Ambulatory Surgical Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Terumo Corporation and Translumina GmbH.